IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that it will host a key opinion leader symposium on the role of survivin in cancer biology and DPX-Survivaca??s potential as a targeted immunotherapeutic agent across a range of tumor types. The event will be held on Thursday, February 27, 2020 from 8:30 a?? 10:00 a.m. ET in New York, NY.

The event will feature presentations by key opinion leaders, including:

Sally P. Wheatley, Ph.D., Assistant Professor, School of Life Sciences, University of Nottingham;

Jeannine Villella, D.O., FACOG, FACS, Chair of Gynecologic Oncology, Department of Obstetrics and Gynecology, Lenox Hill Hospital and NYU Winthrop Hospital; and

Oliver Dorigo, M.D, Ph.D., Associate Professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford University Medical Center.

Additionally, IMV management will provide a corporate update, including an overview of recent data from ongoing studies of DPX-Survivac, which is currently being evaluated in three Phase 2 studies in advanced ovarian cancer, relapsed/refractory diffuse large B-cell lymphoma and a basket of solid tumor indications. Topline results are expected from all three studies in 1H20.

A live webcast of the event will be available under "Events, Webcasts and Presentationsa?? in the Investors section of IMVa??s website and will be available for replay approximately two hours following the live event.

IMV Forward-Looking Statements
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »